That IL-4Rα is overexpressed in pancreatic cancer and downregulation of IL-4Rα by shRNA plasmids resulted in reduced cell growth and migration abilities, combining the impaired IL-4 signaling in pancreatic cancer cells and inhibition on subcutaneous xenograft tumors [90], suggests that IL-4Rα may serve as an attractive target for novel approaches to treating pancreatic cancer. This evidence concerns the gene IL4R and familial pancreatic carcinoma.